SCHEMBL4145681

SCHEMBL4145681

NC(c1ccc(O)c(OCc2ccccc2)c1)c1nccnc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.38
IGF1R P08069 1/20 0.38
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
LTA4H P09960 1/20 0.37
MAPK14 Q16539 1/20 0.37
SIRT1 Q96EB6 1/20 0.36
CHEK1 O14757 1/20 0.36
CDK4 P11802 1/20 0.36
CCNA2 P20248 1/20 0.36
CCND1 P24385 1/20 0.36
CDK2 P24941 1/20 0.36
CCND3 P30281 1/20 0.36
KDR P35968 1/20 0.36
POLB P06746 1/20 0.36
MCL1 Q07820 1/20 0.36
APP P05067 1/20 0.35
HPGD P15428 1/20 0.34
RXRA P19793 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2461436 0.86 PLAU (0.38) PLAULTA4HMAPK14PTGER1
SCHEMBL2459472 0.85 L3MBTL1 (0.48) HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL4154745 0.84 F2 (0.47) POLBHPGDSMN1; SMN2
SCHEMBL27818882 0.84 RXRA (0.41) PLAULTA4HMAPK14HPGDRXRA
SCHEMBL2462329 0.83 F7 (0.37) LTA4HMAPK14PTGER1
SCHEMBL2461700 0.81 NPC1 (0.43) LTA4HNPC1RAB9ASMN1; SMN2
SCHEMBL2459328 0.80 KMT2A (0.52) HPGDRXRARXRBSMN1; SMN2MAOB
Hydrochloric Acid SCHEMBL2463286 0.79 KMT2A (0.51) HPGDSMN1; SMN2MAOB
SCHEMBL2459454 0.76 LMNA (0.41) IGF1RCYP19A1POLBHPGDNPC1
SCHEMBL29113281 0.76 APP (0.44) SIRT1CHEK1CDK4CCNA2CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
EP-1675860-A2 IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-07-05 EP disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed
WO-2005037836-A2 IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 PLAU 3425/4885IGF1R 1/4885CYP19A1 287/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 PLAU 3425/4885IGF1R 1/4885CYP19A1 287/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 PLAU 3425/4885IGF1R 1/4885CYP19A1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.